Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of precision medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age-related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Jun 15, 2021

Renee Agular-Lucander is CEO of Calliditas Therapeutics a Sweden-based clinical-stage biopharmaceutical company focused on the rare kidney disease IgA nephropathy. While there is a genetic predisposition for this autoimmune disease, it is still not clear what triggers the condition and there is no current cure.

Renee talks about:

  • Lead drug candidate Nefecon which starts at the top of the disease cascade in the ileum part of the small intestine. Delivering this disease-modifying agent directly interrupts and disrupts the beginning of the disease
  • How clinical trial data is showing the value of addressing the gut-renal axis and treating this indication in an organ-specific way
  • Other orphan indications that might benefit from this approach
  • What the FDA priority review of Nefecon potentially means for the 1 in every 4 adults with IgAN who will eventually succumb to kidney failure.

@Calliditas1 #IgANephropathy #IgAN #Kidney #KidneyDisease #EndStageRenalDisease #AutoimmuneDisease #Nefecon #RareDisease

Calliditas.se/en

Listen to the podcast here

Calliditas